Monoclonal anti-beta amyloid antibody

A monoclonal antibody, amyloid technology, applied in the direction of antibodies, anti-animal/human immunoglobulin, immunoglobulin, etc., can solve the problem of increased compliance of antibiotic patients

Active Publication Date: 2010-08-11
AC IMMUNE SA +1
View PDF22 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ease of administering antibiotics in oral dosage forms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal anti-beta amyloid antibody
  • Monoclonal anti-beta amyloid antibody
  • Monoclonal anti-beta amyloid antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0430] Example 1: By palmitoylation of Aβ 1-15 Antibodies produced by immunization with supramolecular antigen constructs

Embodiment 11

[0431] Example 1.1: Preparation of palmitoylated Aβ 1-15 Methods for Supramolecular Antigen Constructs

[0432] 1.1.1 Synthesis of tetrakis(palmitoyllysine)-Aβ1-15 peptide antigen

[0433] Palmitoylated amyloid 1-15 peptides were synthesized following a modification of a previously reported method (Nicolau et al. 2002). This new method involves grafting palmitic acid onto the terminal Lys residue of a preformed peptide on the resin, instead of incorporating the modified amino acid 9-fluorenylmethoxycarbonyl (Fmoc)-Lys(Pal)-OH Stepwise solid-phase synthesis. This new method increases the coupling efficiency and provides a considerably higher purity product. Therefore, applying [hexafluorophosphate 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium] (HBTU) coupling chemistry, the orthogonally protected amino acid Fmoc -Lys(Mtt)-OH is attached to Wang resin. The Fmoc group was removed with 20% piperidine in DMF and a second Fmoc-Lys(Mtt)-OH residue was coupled. The next 15...

Embodiment 12

[0434] Example 1.2: Antibodies Raised by Supramolecular Antigen Constructs

[0435] Preparation against palmitoylated Aβ 1-15 mAbs generated from supramolecular antigen constructs

[0436] Using palmitoylated antigens (ACI-24, Aβ 1-15 ) to immunize C57BL / 6 mice at 2-week intervals. 10-12 animals were immunized with each antigen (injection volume: 200 μl, containing 8 nmol peptide). Animals were sacrificed 4 days after the last injection. After 5 booster immunizations, mice with therapeutic titers (ELISA positive at 1:5,000 dilution of serum) were selected for fusion. Splenocytes are collected from immunized animals, and hybridomas are generated by fusing the primed splenocytes with a myeloma cell line. Mouse B lymphocytes from spleen and bone marrow were performed using the well-known methods of Kohler and Milstein (Nature 256:495-497 (1975)) and Harlow and Lane (Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory, New York 1988)). Fusion of tumor cell line SP...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present application is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present application provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ss-amyloid proteins. The antibodies enabled by the teaching of the present application are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

Description

[0001] Cross references to related patent applications [0002] This application claims U.S. Provisional Application No. 60 / 943,543, filed June 12, 2007, U.S. Provisional Application No. 60 / 943,541, filed June 12, 2007, and U.S. Provisional Application No. .60 / 943,790 priority. Background of the invention [0003] The present invention relates to methods and compositions for diagnostic and therapeutic use in the treatment of diseases and disorders caused by or associated with amyloid or amyloid-like protein, including Amyloidosis, a group of disorders and abnormalities related to amyloid protein, such as Alzheimer's disease. [0004] Amyloidosis is not a single disease entity but a broad group of progressive disorders characterized by extracellular tissue deposits of waxy amyloid proteins called amyloids that accumulate in one or more organs or body systems disease process. As amyloid deposits build up, they begin to interfere with the normal function of an organ or body sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18A61K39/395A61P25/28C12N5/20
CPCC07K16/18C07K2317/565A61K2039/6093A61K2039/505A61K2039/6018C07K2317/56A61P21/00A61P21/04A61P25/00A61P25/16A61P25/18A61P25/28A61P27/02A61P3/10A61P31/18A61P35/00
Inventor A·普法伊费尔M·皮尔格伦A·穆斯R·沃茨
Owner AC IMMUNE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap